CVS Health Corp. stock gains on strong earnings and analyst upgrade

Published on 09/20/2026 at 14:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health Corp. stock opened at USD 89.02 on September 18, 2026 after delivering stronger-than-expected quarterly results with double-digit EPS growth. Wall Street Zen raised its rating to strong-buy and the average analyst price target stands at USD 107.24.

Moderner Apothekenverkaufsraum mit Apothekerin und Kundin vor Medikamentenregalen — CVS Health Corp. zeigt fotorealen Apothekenverkaufsraum mit Apothekerin und Kundin, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health Corp. stock (ISIN US1266501006) opened at USD 89.02 on September 18, 2026 on the New York Stock Exchange, trading below the average analyst price target of USD 107.24 and reflecting a market still digesting the latest results and rating changes.

Strong quarterly figures and guidance

According to MarketBeat on September 20, 2026, CVS Health reported adjusted earnings per share of USD 2.58 for its most recent quarter, clearly beating the consensus estimate of USD 1.87 and delivering a positive surprise of USD 0.71 per share.

In the same report, quarterly revenue was stated at USD 106.1 billion, with sales increasing 7.3 percent year over year, a growth rate that underlines the scale of CVS Health's integrated health services and retail operations in the latest reporting period.

For the current fiscal year 2026, CVS Health set its adjusted EPS guidance in a range of USD 7.90 to USD 8.10, as highlighted by MarketBeat, giving investors a numerical benchmark for earnings power over the full year.

Analyst upgrade and consensus targets

As MarketBeat reports, Wall Street Zen upgraded CVS Health from a buy rating to a strong-buy rating in a report dated September 20, 2026, signaling increased conviction in the stock following the earnings beat and guidance.

According to the same overview from MarketBeat, CVS Health currently carries 22 buy ratings and one hold rating from investment analysts, resulting in a consensus assessment of moderate buy with an average price target of USD 107.24.

The opening price of USD 89.02 on September 18, 2026 therefore sits materially below the consensus target, giving a gap of USD 18.22 between the current trading level and the average analyst expectation, a difference many investors may view as potential upside if the company executes on its guidance.

Investor positioning and risk context

Institutional investors hold approximately 80.66 percent of CVS Health shares, with notable second-quarter buying by BlackRock, Wellington Management and Bank of America mentioned in the analyst commentary from MarketBeat, a level of institutional participation that tends to stabilize trading but can also amplify moves when sentiment changes.

At the same time, the MarketBeat summary notes that one comment on CVS Health's earnings call contributed to a short-term setback in the stock, illustrating that despite solid headline figures, investor focus also remains on operational risks, reimbursement issues and the trajectory of the health care segment, which can quickly affect valuation.

CVS Health also appears in bond fund holdings, with one bond ETF overview from The Globe and Mail mentioning CVS Health Corp bonds among the largest positions, highlighting how the company's credit profile feeds into fixed income strategies as well as equity portfolios.

Stock level and trading perspective

Shares of CVS Health opened at USD 89.02 on the New York Stock Exchange on September 18, 2026, as stated in the analyst coverage by MarketBeat, and this level forms the reference point for recent trading and for comparison with the USD 107.24 consensus price target.